Skip to main content

$1.55 -0.01 (-0.32%)

High

$1.56

Low

$1.52

Trades

1,747

Turnover

$1,891,056

Volume

1,225,647
30 June 2023 at 4:10pm
Register to track PNV and receive email alerts.

PolyNovo Limited designs, manufactures, and sells biodegradable medical devices in the United States, Australia, New Zealand, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, a dermal scaffold for the regeneration of the dermis when lost through extensive surgery, trauma, or burn. It is also developing hernia devices for hernia repair and solution for ventral hernia and complex abdominal wall reconstruction; NovoSorb Dermal Beta Cell, a novel intracutaneous ectopic pancreas to treat type 1 diabetes; NovoSorb MTX for single stage grafting in burns, chronic, and surgical wounds; and plastics and reconstructive device products. The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was incorporated in 1998 and is headquartered in Port Melbourne, Australia.

Expand Company Description

Market Cap (10-Oct)

$1,688,898,304 (311th)

Close (30-Jun)

$1.55

Volume (30-Jun)

1,225,647

Shortsold (23-Sep)

11,869,385 (1.72%) (140th)

52w High

$2.78

52w Low

$1.10

P/E

147.06

EPS

0.01
Subject
PNV Ann: Appendix 3Y - Robyn Elliott

PNV Ann: Director Share Purchase - David Williams

PNV Ann: Director Share Purchase - David Williams

PNV Article: ASX slips; Goldman forecasts cash rate to peak at 4.85pc

PNV Article: ASX edges up; Goldman forecasts cash rate to peak at 4.85pc

PNV Article: ASX flat; yield curve inverts, flashes recession signal

PNV Ann: First ever A$7M Sales Month

PNV Article: PolyNovo tipped to post record sales

PNV Ann: Trading Halt

PNV Ann: Pause in Trading

PNV Ann: Notification regarding unquoted securities - PNV

PNV Ann: PolyNovo presents at Macquarie Australia Conference

PNV Ann: NovoSorb MTX First Sales and March 2023 $6m Revenue

PNV Ann: Trading Halt

PNV Ann: Application for quotation of securities - PNV

PNV Ann: Change of Director's Interest Notice

PNV Ann: Application for quotation of securities - PNV

PNV Ann: S&P DJI Announces March 2023 Quarterly Rebalance

PNV Ann: 1H FY23 Results - Webcast Recording

PNV Ann: PolyNovo presents at Macquarie Bank

PNV Ann: 1H FY23 Results Presentation

PNV Ann: Appendix 4D and 1H FY23 Report

PNV Ann: Appendix 3Y - Robyn Elliott

PNV Ann: Appendix 3Y - Christine Emmanuel

PNV Ann: Appendix 3Y - Andrew Lumsden

PNV Ann: Appendix 3Y - Bruce Rathie

PNV Ann: Appendix 3Y - David Williams

PNV Ann: Cleansing Notice

PNV Ann: Application for quotation of securities - PNV

PNV Ann: Update - SynPath Diabetic Foot Ulcer Trial

PNV Ann: Webcast details - 1HFY23 Results

PNV Ann: Results of General Meeting

PNV Article: ASX rises 0.8pc; Ioneer soars 21pc; Baby Bunting dives

PNV Article: ASX to rise; PolyNovo posts record first-half sales

PNV Article: Bain Capital to seek advice on Virgin Australia IPO

PNV Ann: 1H23 Indicative Trading Result (unaudited)

PNV Ann: Presentation slides - J.P. Morgan Healthcare Conference

PNV Ann: Presentation to J.P. Morgan Healthcare Conference

PNV Ann: Application for quotation of securities - PNV

PNV Ann: Successful Completion of Share Purchase Plan

PNV Ann: Webcast Recording - Investor Presentation and Update

PNV Ann: Notice of General Meeting

PNV Ann: Webcast Agenda - Investor Presentation and Update

PNV Ann: Amended Weblink - Investor Presentation & Update 5 Dec 2022

PNV Ann: Investor Presentation & Update - Webcast 5 Dec 2022

PNV Ann: Share Purchase Plan (SPP) Offer

PNV Ann: Cleansing Notice

PNV Ann: Application for quotation of securities - PNV

PNV Ann: Ceasing to be a substantial holder

PNV Article: NZ dollar jumps after RBNZ lifts rates by record 0.75pc

Register to track PNV and receive email alerts.

Similar Companies

ANN
AVR
MGZ
NAN
NXS
OSX
SDI
SDI